Effectiveness of BA.1- and BA.4/BA.5-containing bivalent COVID-19 mRNA vaccines against symptomatic SARS-CoV-2 infection during the BA.5-dominant period in Japan

Takeshi Arashiro ORCID logo; Yuzo Arima; Jin Kuramochi; Hirokazu Muraoka; Akihiro Sato; Kumi Chubachi; Atsushi Yanai; Hiroko Arioka; Yuki Uehara; Genei Ihara; +22 more... Yasuyuki Kato; Naoki Yanagisawa; Akihiro Ueda; Hideaki Kato ORCID logo; Hideaki Oka; Yusuke Nishida; Yuki Nidaira; Takahiro Asami ORCID logo; Torahiko Jinta; Akira Nakamura; Kunihiro Oba; Daisuke Taniyama; Kei Yamamoto; Katsushi Tanaka; Kankuro Ueshima; Tetsuji Fuwa; Ashley Stucky; Tadaki Suzuki; Chris Smith ORCID logo; Martin Hibberd; Koya Ariyoshi ORCID logo; Motoi Suzuki; (2023) Effectiveness of BA.1- and BA.4/BA.5-containing bivalent COVID-19 mRNA vaccines against symptomatic SARS-CoV-2 infection during the BA.5-dominant period in Japan. Open forum infectious diseases. ISSN 2328-8957 DOI: 10.1093/ofid/ofad240
Copy

In this multi-center prospective test-negative case-control study in Japan, the effectiveness of both BA.1-containing and BA.4/BA.5-containing bivalent COVID-19 mRNA vaccines against symptomatic infection during the BA.5-dominant period was high compared to no vaccination (65% and 76%) and moderate compared to monovalent vaccines administered over half a year before (46% combined).


picture_as_pdf
Arashiro-etal-2023-effectiveness-of-BA1.pdf
subject
Published Version
Available under Creative Commons: NC-ND 3.0

View Download

Atom BibTeX OpenURL ContextObject in Span Multiline CSV OpenURL ContextObject Dublin Core Dublin Core MPEG-21 DIDL EndNote HTML Citation JSON MARC (ASCII) MARC (ISO 2709) METS MODS RDF+N3 RDF+N-Triples RDF+XML RIOXX2 XML Reference Manager Refer Simple Metadata ASCII Citation EP3 XML
Export

Downloads